Q-omics provides the consensus-scored PEAR1 profile across patient tissues and cancer cell-line models. PEAR1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PEAR1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, PEAR1 RNA expression shows 19,368 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, LUAD, and THYM as cancer lineages where PEAR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEAR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEAR1 survival associations across molecular data types. PEAR1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEAR1 RNA expression–survival associations across cancer types. High PEAR1 expression shows unfavorable associations in CESC, KIRP, MESO and LAML, but favorable associations in UCS and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PEAR1 RNA expression.
This table summarizes PEAR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PEAR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEAR1 shows lower tumor expression in LUAD, THCA, LUSC, KIRP and KICH and higher tumor expression in HNSC. The LUAD box plot shows higher PEAR1 RNA expression in normal versus tumor tissue (log2 FC = −2.194, t-test p < 0.001).
This table shows molecular features associated with PEAR1 in patient tissues and cancer cell lines. In patient samples, PEAR1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PEAR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
